Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Income from Continuing Operations (2020 - 2025)

Apellis Pharmaceuticals has reported Income from Continuing Operations over the past 6 years, most recently at 203577000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 203577000.0 for Q4 2025, down 1393.81% from a year ago — trailing twelve months through Dec 2025 was 122238000.0 (up 30.21% YoY), and the annual figure for FY2025 was 122238000.0, up 30.22%.
  • Income from Continuing Operations for Q4 2025 was 203577000.0 at Apellis Pharmaceuticals, down from 215715000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for APLS hit a ceiling of 402697000.0 in Q4 2022 and a floor of 219191000.0 in Q2 2021.
  • Median Income from Continuing Operations over the past 5 years was 107131000.0 (2023), compared with a mean of 61225800.0.
  • Peak annual rise in Income from Continuing Operations hit 475.46% in 2025, while the deepest fall reached 1393.81% in 2025.
  • Apellis Pharmaceuticals' Income from Continuing Operations stood at 283396000.0 in 2021, then soared by 42.1% to 402697000.0 in 2022, then crashed by 122.0% to 88585000.0 in 2023, then skyrocketed by 84.62% to 13628000.0 in 2024, then plummeted by 1393.81% to 203577000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 203577000.0 (Q4 2025), 215715000.0 (Q3 2025), and 42151000.0 (Q2 2025) per Business Quant data.